ATRA vs PATH
Atara Biotherapeutics Inc (ATRA) versus Uipath Inc (PATH) — a side-by-side from cached financials, not a winner call.
Atara Biotherapeutics Inc (ATRA) is a biotechnology company listed on NASDAQ.
Uipath Inc (PATH) is a software - infrastructure company listed on US.
Latest reported ATRA revenue for 2024-12-31 was $128.9M. Net income was -$85.4M. Revenue was up 1404.0% from 2023-12-31 to 2024-12-31. ATRA currently screens at market cap $87.1M.
Latest reported PATH revenue for 2026-01-31 was $1.61B. Net income was $282.3M. Revenue was up 12.7% from 2025-01-31 to 2026-01-31. PATH currently screens at market cap $6.07B and trailing P/E 19.4.
ATRA currently screens at market cap $87.1M. PATH currently screens at market cap $6.07B and trailing P/E 19.4.
Not investment advice. Open the ATRA and PATH stock pages for the full models.
Not investment advice.